Inhibition of DC migration in the steady state by RvE1 or a BLT1 antagonist. (A) Schema of photoconversion. Kaede transgenic mice were treated with vehicle, RvE1 (200 ng/mouse), or a BLT1 antagonist (ONO-4057; 60 µg/mouse). Then the shaved abdominal skin was irradiated with violet light (photoconversion) 30 min after the drug administration. 24 h after the photoconversion, the draining axillary and popliteal LNs were collected, stained with anti-CD11c and MHC class II mAbs, and subjected to flow cytometric analysis. (B) Representative FACS plots gated on CD11c⁺ MHC class II⁺ cells in each condition. Numbers within the red squares indicate the percentage of migrated cells (Kaede-red cells) among total CD11c⁺ MHC class II⁺ cells. (C) Quantification of the Kaede-red–positive CD11c⁺ MHC class II⁺ cells in dLNs (n = 3). (D) The numbers of each DC subset (EpCAM⁺ Langerhans cells, CD103⁺ dermal DCs, and CD103⁻ dermal DCs among Kaede-red⁺ CD11c⁺ MHC class II⁺ cells in dLNs; n = 3). Results are expressed as the mean ± SEM. All p-values were obtained by Student’s t test: *, P < 0.05. All data are representative of three independent experiments with reproducible results.